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Abstract
 
Dendritic cells (DCs) are not targets for infection by the transforming Epstein-Barr virus (EBV).
To test if the adjuvant role of DCs could be harnessed against EBV latency genes by cross-pre-
sentation, DCs were allowed to process either autologous or human histocompatibility leuko-
cyte antigen (HLA)-mismatched, transformed, B lymphocyte cell lines (LCLs) that had been
subject to apoptotic or necrotic cell death. After phagocytosis of small numbers of either type of
 
dead LCL, which lacked direct immune-stimulatory capacity, DCs could expand CD8
 
1
 
 T cells
capable of killing LCLs that were HLA matched to the DCs. Necrotic EBV-transformed, major
histocompatibility complex (MHC) class I–negative LCLs, when presented by DCs, also could
elicit responses to MHC class II–negative, EBV-transformed targets that were MHC class I
matched to the DCs, confirming efficient cross-presentation of LCL antigens via MHC class I
 
on the DC. Part of this EBV-specific CD8
 
1
 
 T cell response, in both lytic and interferon 
 
g
 
 se-
cretion assays, was specific for the EBV nuclear antigen (EBNA)3A and latent membrane pro-
tein (LMP)2 latency antigens that are known to be expressed at low levels in transformed cells.
The induced CD8
 
1
 
 T cells recognized targets at low doses, 1–10 nM, of peptide. Therefore,
the capacity of DCs to cross-present antigens from dead cells extends to the expansion of high
affinity T cells specific for viral latency antigens involved in cell transformation.
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Introduction
 
Peptides from infected or malignant cells can be presented
on the MHC products of bone marrow–derived APCs (1).
As the donor cells and APCs need not be genetically
matched at the MHC, antigens effectively “cross” from
one cell to another. Cross-presentation has been known for
some time (2), but only recently have important mechanis-
tic aspects become apparent. Dendritic cells (DCs) prove to
be particularly efficient in cross-presenting antigens on
both MHC class I and II (3–5). For MHC class I, cross-
presentation is also termed the exogenous pathway, as the
presented viral or tumor peptides need not be synthesized
endogenously in the APC cytoplasm. Nevertheless, trans-
porters associated with antigen processing (TAP) seem cru-
cial (1, 5). The sources of antigen include virus particles (6),
bacteria (7), exosomes (8), immune complexes (5), and dy-
ing cells (3, 9).
 
Cross-presentation of dead and dying cells is of special in-
terest in the context of tumor immunology. Tumor cells
typically lack costimulatory molecules, so the processing of
tumor cells can lead to the display of multiple cancer anti-
gens on potent DCs, improving immunogenicity. At this
time, cross-priming during virus infection has been studied
with infectious viruses like influenza and vaccinia (1, 3),
rather than oncogenic viruses in latency or nonlytic states.
In other words, the significance of cross-presentation would
be greatly enhanced if one could demonstrate that latent an-
tigens are processed, and that the corresponding primed T
cells recognize epitopes naturally presented on intact trans-
formed cells. For EBV, latency states are associated with
transformation, so cross-presentation provides a way to
elicit immunity to EBV antigens expressed in tumors like
Hodgkin’s lymphoma and nasopharyngeal carcinoma. Here
we describe the cross-presentation by human DCs of anti-
gens from dying B lymphocyte cell lines (LCLs) trans-
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formed with EBV. We will show that human DCs cross-
present apoptotic and necrotic LCLs, giving rise to CD8
 
1
 
effectors that directly recognize HLA-matched, transformed
B cell lines, including such important latency gene products
as (EBV nuclear antigen) EBNA3A and latent membrane
protein (LMP)2. These findings provide a rationale for the
testing of DCs loaded with dead tumor cells to elicit immu-
nity to EBV-associated malignancies in vivo.
 
Materials and Methods
 
EBV-transformed LCLs.
 
LCLs were derived from PBMCs of
serologically MHC class I–typed donors, using the supernatant of
the marmoset line B95-8 added in the presence of 1 
 
m
 
g/ml cy-
closporin A in RPMI 1640/20% FCS/glutamine/gentamicin. In
addition, LCL721.221 (10) and T2 (11) cells were used. All es-
tablished cell lines were grown in RPMI 1640/10% FCS/
glutamine/gentamicin.
 
DCs and T Cells.
 
As described (12), PBMCs from leukocyte
concentrates (buffy coats) or whole blood were isolated on Fi-
coll-Paque (Amersham Pharmacia Biotech) and separated by ro-
setting into T cell enriched (ER
 
1
 
) and depleted (ER
 
2
 
) popula-
tions. DCs were generated in 3-ml cultures of 2.5 
 
3
 
 10
 
6
 
 ER
 
2
 
cells with 1% human single donor plasma, recombinant human
(rh)GM-CSF and rhIL-4 in a standard way (12) for 6 d, where-
upon nonadherent immature DCs were transferred to new plates
at 3 
 
3 
 
10
 
5
 
 cells/ml. Half the medium was replaced by monocyte-
conditioned medium (MCM) as a maturation stimulus. After
48 h, mature DCs were used fresh or after cryopreservation to
stimulate T cells at a ratio of 1:30 in RPMI 1640/5% human se-
rum/glutamine/gentamicin. CD4
 
1
 
 or CD8
 
1
 
 fractions were se-
lected from ER
 
1
 
 cells with anti-CD4 or anti-CD8 Microbeads,
an MS
 
1
 
/RS
 
1
 
 column, and a MiniMACS separator (Miltenyi
Biotec). PHA blasts were generated from ER
 
1
 
 cells with 1 
 
m
 
g/ml
PHA (Sigma-Aldrich) in RPMI 1640/10% FCS/glutamine/gen-
tamicin in 3–5 d.
 
Induction and Detection of Apoptosis and Necrosis in LCLs.
 
Ap-
optosis was induced with a 60-mJ UV-B light (UVB) lamp
(Derma Control, Inc.), calibrated to provide 2 mJ/cm
 
2
 
/s, and ne-
crosis either by four freeze–thaw cycles or heating at 56
 
8
 
C for 30
min. Cell death was monitored using the Early Apoptosis Detec-
tion kit (Kayima Biomedical) to stain with annexin V-FITC
(early apoptosis) and PI (primary or secondary necrosis).
 
DC Phagocytosis of Apoptotic or Necrotic Cells.
 
8 h after LCLs
were induced to undergo apoptosis or necrosis, immature DCs
were added at a ratio of 1:1. DCs were matured by adding
MCM. To separate DCs from the LCLs for the experiments rep-
resented by Fig. 4, b and c, DCs were stained with PE–anti-
CD11c (Becton Dickinson) and isolated with anti-PE Micro-
Beads, MS
 
1
 
/RS
 
1
 
 column, and MiniMACS separator. More than
95% of the beaded cells were CD11c-PE
 
1
 
, CD83-FITC
 
1
 
, and
CD20-FITC
 
2
 
. To follow phagocytosis, LCLs were dyed red
with PKH26 before inducing cell death and immature DCs green
with PKH67 (Sigma-Aldrich). After coculture for 12 h at a ratio
of 1:1 at 4
 
8
 
C and 37
 
8
 
C, phagocytosis was monitored as double-
positive cells on the FACS
 
®
 
, or by applying DCs to alcian blue–
coated slides for two-color fluorescence microscopy using an
Olympus epifluorescence microscope. The motorized stage al-
lowed to take 0.5-mm optical sections with a cooled CCD cam-
era (Hamamatsu) and Metamorph software (Universal Imaging
Corp.). Images were deconvoluted by applying a nearest neigh-
bor algorithm provided by Metamorph.
 
Vaccinia Virus Recombinants and Infection of DCs.
 
Recombi-
nant vaccinia viruses (vv) were expanded on adherent rabbit
RK13 cells and titrated on monkey BSC40 kidney cells. Vv was
added to mature DCs at a multiplicity of infection (MOI) of 2:1
for 1 h at 37
 
8
 
C and washed three times with 5% pooled human
serum (PHS). The rate of infection was checked after 6–12 h by
FACS
 
®
 
 using intracellular staining for a 29-kD vaccinia early pro-
tein with VV1-6B6 antibody (12).
 
Peptide Loading of DCs.
 
The synthetic peptides FLR-
GRAYGL (HLA-B8
 
1
 
/EBNA 3A) and CLGGLLTMV (HLA-
A2/LMP 2) were purchased from Genemed Synthesis or Re-
search Genetics, and added to APCs and targets at 1 
 
m
 
M in
RPMI 1640 for 1 h at 37
 
8
 
C.
 
T Cell Assays.
 
IFN-
 
g
 
 enzyme-linked immunospot (ELISPOT)
and 4-h Na
 
2
51
 
CrO
 
4
 
 cytolysis assays were carried out in a standard
way as described (12).
 
Results
 
DCs Phagocytose Apoptotic or Necrotic LCLs.
 
We first
studied DC phagocytosis of apoptotic and necrotic LCLs.
Figure 1. Immature DCs
phagocytose dying LCLs. (A)
Annexin V/PI staining 6 h after
UV-B treatment for 4 min (ap-
optosis), four freeze–thaw cycles,
or heating at 568C for 30 min
(necrosis). (B)  Immature DCs
stained with PKH 67 (green),
and dying LCLs stained with
PKH 26 (red) before inducing
cell death, were cultured at 1:1.
Phagocytosis was assessed as DCs
double positive for apoptotic (top) or necrotic (bottom) LCLs. FACS®
analyses was performed at different time points, with the optimum phago-
cytosis at 12 h. To rule out binding vs. uptake of LCLs, cells were cocul-
tured at 48C (left). (C) Fluorescence microscopy showed that z50% of
the green DCs (dark fluorescence here) had one or more small red LCL
fragments (light fluorescence and arrow) inside the cell (see the XZ plane). 
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Apoptosis was induced by UV-B, and necrosis by either
four cycles of freeze–thawing or heating at 56
 
8
 
C for 30
min. LCL death was monitored at several times using the
FACS
 
®
 
 and staining for annexin V-FITC and PI. Annexin
V single-positive LCLs (apoptosis) predominated 6 h after
UV-B, and annexin V/PI double positives (necrosis) after
repeated freeze–thaw cycles (Fig. 1 A). Freeze–thawing
killed most cells, but live cells remained after UV-B treat-
ment (Fig. 1 A). To follow phagocytosis, the LCLs were la-
beled with PKH26 before induction of cell death, and 8 h
later, immature PKH67-labeled DCs were added at a ratio
of 1:1. After 12 h of DC/LCL coculture (for maximal up-
take), 
 
z
 
50% of the DCs stained double positive (Fig. 1 B).
Some DCs might not have taken up dying LCLs, because
immature DCs generated with GM-CSF and IL-4 con-
tained an already mature, less phagocytic fraction. No dou-
ble-positive DCs were seen in cocultures on ice (Fig. 1 B).
Phagocytosis of LCL fragments by DCs was verified by flu-
orescence microscopy (Fig. 1 C), whereas LCLs were inca-
pable of endocytosing LCL fragments under the same con-
ditions (data not shown). Therefore, 
 
z
 
50% of cultured
DCs took up dying apoptotic or necrotic LCLs within 12 h.
 
Cross-presenting DCs Induce CTLs that Lyse LCLs HLA-
matched to the DCs.
 
To formally establish presentation
across the MHC, we cocultured immature DCs with dead
HLA-mismatched LCLs (HLA typing in figure legends) for
2 d and tested if the DCs would expand T cells that could
kill LCLs HLA-matched to the DCs. To mature the DCs,
we added MCM along with the dying cells. As expected,
MCM induced a mature phenotype, i.e., CD83, CD25,
and high CD86 and HLA-DR. The DC phenotype was
similar whether or not they had fed on dying apoptotic or
necrotic cells (not shown). The DCs then were used to
stimulate ER
 
1
 
 T cells for 14 d, with one restimulation on
day 7 with IL-2. HLA-B8
 
1
 
 DCs that had taken up HLA-
B8
 
2
 
 LCLs elicited CTLs that killed HLA-B8–matched, but
not HLA-B8–mismatched, LCLs (Fig. 2 A). Necrotic and
apoptotic LCL fragments were similarly active as sources of
LCL antigens (Fig. 2 A). DCs or dead LCLs by themselves
were incapable of stimulating T cells; in fact, mixtures of
DCs and dead HLA-mismatched LCLs did not induce lysis
of the HLA-mismatched LCLs used for the coculture (Fig.
2 A). This indicates that apoptotic and necrotic cellular
fragments lack either sufficient native HLA molecules and/
Figure 2. DCs induce CTLs that lyse HLA class I–matched but
not mismatched LCLs, after phagocytosis of allogeneic, HLA-mis-
matched apoptotic or necrotic LCLs. (A) Left. Mature donor A
DCs alone did not stimulate significant cytolysis of HLA class
I–matched donor B (HLA A22B81 LCL: HLA-A1, A3, B7, B8,
Bw6, Cw7, DR4, DRw14, DRw52, DRw53, and DQw3) or
mismatched donor C (HLA A21B82 LCL: HLA-A2, A24, B38,
B46, Bw4, Cw1, DRB1*1502, DRB1*0901, DRB5*0101,
DRB4*01, DQB1*0502, and DQB1*0303) LCLs. Middle and
right. Donor A DCs, loaded with apoptotic or necrotic mis-
matched donor C LCLs, stimulated donor A CTLs against HLA-
B8 matched donor B but not mismatched donor C LCLs (middle
and right). One of three similar experiments. (B) Left. Mature
HLA-A21 DCs alone did not stimulate cytolysis against HLA-A21,
HLA class II–negative, EBV1 T2 cells (HLA-A21 and low for
HLA-B5 and Cw1) or autologous PHA blasts. After loading with
necrotic HLA class Ia–negative, EBV1 LCL721.221 cells (HLA-
DR1, DQ1, DP1) or pulsing with 1 mM LMP2426–434 peptide, the
DCs stimulated autologous CTLs recognizing HLA-A21 EBV1
T2, but not HLA-A21 EBV2 PHA blasts. One of two experiments. 
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or costimulatory molecules to evoke direct alloreactivity.
In addition, alloreactivity mediated through MHC-derived
peptides processed from LCL was not formally required to
induce lytic T cells, as shown by the use of select LCLs in
the experiments of Fig. 2 B. Here, HLA-A2
 
1
 
 DCs were
cocultured with necrotic LCL721.221 cells that lacked
MHC class Ia products. The T cells expanded by the
DCs were nevertheless capable of lysing MHC class II
 
2
 
 T2
cells that were EBV
 
1
 
 and HLA-A2
 
1
 
. These cultures also
 
showed only background reactivity against PHA blasts au-
tologous to the DCs. As T2 cells are TAP-deficient, the ly-
sis in Fig. 2 B is probably due to recognition of EBV pep-
tides presented in a TAP-independent manner as described
for the LMP2
 
425
 
2
 
434 
 
epitope (13) and formally established
below in Fig. 4 C. Accordingly, T cells stimulated with
LMP2
 
425
 
2
 
434
 
 on DCs were used as a positive control, and
untreated DCs as a negative control in Fig. 2 B. Therefore,
even when exposed to low doses of dead allogeneic LCLs,
DCs can cross-present EBV antigens that ultimately are
presented by other LCLs HLA-matched to the DCs.
 
DCs Cross-present Apoptotic or Necrotic, Allogeneic, and Au-
tologous LCLs to CD8
 
1
 
 T Cells.
 
To verify that the lysis of
LCLs in Fig. 2 was mediated by CD8
 
1
 
 T cells, we again fed
DCs with apoptotic or necrotic LCLs during their matura-
tion, but then added CD8
 
1
 
 or CD4
 
1
 
 selected T cells for 14 d.
Figure 3. CD81 T cells are effectors for HLA class I–matched LCLs af-
ter cross-presentation by DCs. (A) HLA-A21B82 DCs were cultured
with allogeneic HLA-A2-B81 LCLs (HLA-A*0101 homozygous,
B*4002, B*0801, C*0304, C*0701, DRB1*0301, DRB1*1101,
DQB1*0201, and DQB1*0301) at a ratio of 1:1 during maturation. The
DCs were added to CD81 or CD41 positively selected T cells for 14 d.
Lytic activity (4 h 51Cr release assay) is shown on HLA-A21B81 (HLA-
A2, A1, B39, B8, Cw7, DR1, DR9, DQ1, and DQ3) or HLA-A22B82
(HLA-A*3001, A*3201, B*1302, B*4402, C*0602, C*0501,
DRB1*0401, DRB1*0701, DRB4*01, DQB1*0302, and DQB1*0201)
LCLs, at E/T ratios of 20:1. (B) HLA-A21B81 DCs, after loading with
autologous necrotic or apoptotic LCLs for 2 d in MCM, were added to
CD81 T cells (ratio 1:30). On day 7, wells were split for ELISPOT assays
to detect IFN-g upon restimulation with autologous vs. allogeneic HLA-
A22B82 LCLs. Necrotic LCLs alone did not expand LCL-specific T
cells. One of two similar experiments. SFC, spot-forming cell; apop, ap-
optotic; necr, necrotic.
Figure 4. The EBV latent antigens EBNA3A and LMP2 are cross-
presented by DCs on MHC class I. (A) HLA-A21 DCs were allowed to
phagocytose allogeneic, apoptotic (UVB), or necrotic (freeze–thaw [FT])
LCLs during maturation. The DCs were cultured with syngeneic T cells,
and 7 d later, ELISPOT assays were run with control recombinant vac-
cinia (vvTK2), vvLMP1, or vvLMP2. SFC, spot-forming cell. (B) HLA-
A21B81 DCs were cultured with apoptotic (UVB) or necrotic (FT)
HLA-A22B82 LCLs for 2 d in the presence of a maturation stimulus.
Then the DCs were stained with anti–CD11c-PE, isolated with mag-
netic anti-PE beads, and cocultured with ER1 T cells at a ratio of 1:30.
7 d later, IFN-g–secreting T cells were quantified after no restimulation
or restimulation with EBNA3A3252333 peptide. (C) HLA-A21 DCs were
charged for 2 d with necrotic (heated) HLA-A22 allogeneic LCLs or
with LMP24262434 peptide, and simultaneously matured with MCM. Ma-
ture CD11c-PE1 cells were selected with anti-PE beads and used to
stimulate autologous CD81 T cells. After day 14, T cells were tested in
an IFN-g ELISPOT assay with LMP24262434 peptide. One of three simi-
lar experiments.409 Subklewe et al. Brief Definitive Report
The DCs and target LCLs were not HLA-DR matched
(Fig 3, legend), so one would not expect CD41 CTLs as
occurs with responses to EBNA1 (4). In fact, cross-presen-
tation expanded CD81 T cells that lysed class I–matched
LCLs, whereas CD41 T cells showed only background lysis
against the HLA class II–mismatched targets (Fig. 3 A).
We then verified that DCs expand CD81 T cells after
uptake of autologous, necrotic, or apoptotic LCLs (Fig. 3
B). These T cells secreted IFN-g (ELISPOTs) in response
to the autologous LCLs, but not to HLA-A2/B8–mis-
matched LCLs. Dead autologous LCLs alone did not ex-
pand specific CD81 T cells whether the LCLs were killed
via necrosis (Fig. 3 B) or apoptosis (not shown). Therefore,
DCs are able to process allogeneic or autologous LCLs,
directly stimulating CD81 T cells reactive with LCLs
matched at HLA class I loci to the DCs.
DCs Cross-present Defined EBV Latency Gene Products from
Dying LCLs. We next tested for cross-presentation of
known EBV latency gene products. DCs charged with a
low dose of dead LCLs were used to stimulate purified
CD81 T cells for 1 wk. In Fig. 4 A, cross-presentation of
HLA-A22 LCLs allowed HLA-A21 DCs to expand CD81
T cells specific for the LMP2 EBV latency antigen, i.e.,
HLA-A21 DC targets were recognized by the cultures after
infection with vvLMP2 but not vv control (vvTK2), or
vvLMP1. To extend these experiments, we purified the
DCs (see Materials and Methods) away from residual dying
LCLs before the DC-T cell coculture. We used anti-
CD11c magnetic bead selection, as CD11c is abundant on
DCs but not detectable on LCLs. The purified DCs from
HLA-B81 and/or HLA-A21 donors processed the domi-
nant known latency T cell epitopes from allogeneic LCLs,
specifically EBNA3A3252333 (restricted by HLA-B8; Fig. 4
B) and LMP24262434 (restricted by HLA-A2; Fig. 4 C).
High Functional Affinity of CD81 T Cells Expanded by
DCs Cross-presenting LCLs. We used the ELISPOT assay
to compare the functional affinity of CD81 T cells ex-
panded by DCs pulsed with viral peptide or cross-present-
ing necrotic LCLs. After a week of DC-T cell coculture,
we added graded doses of peptide directly to the assay,
avoiding further addition of APCs that increased antigen-
independent backgrounds. Both forms of DCs expanded
CD81 T cells of comparable epitope affinity, as indicated
by titrations of FLRGRAYGL peptide (Fig. 5). Half-maxi-
mal IFN-g responses occurred at 1–10 nM peptide (Fig. 5).
Therefore, DCs extract EBNA3A peptide from latently in-
fected LCLs, and the ensuing cross-presentation generates
CD81 T cells with a high functional affinity.
Discussion
DCs efficiently cross-present dying virus-infected cells
(3). We now find that DCs also cross-present virus-trans-
formed B cells. This extends the exogenous pathway for
MHC class I in several directions: to the processing of B
cells, to viral antigens expressed during latency, and to anti-
gens (EBNA3A, LMP2) that are expressed endogenously
and are likely to be critical for oncogenesis. Importantly,
the cross-presentation we have studied does not require en-
hanced antigen expression by productive infection, exoge-
nous interferons, or viral vectors and promoters. Also,
transformed LCLs are direct targets for cross-primed CD81
T cells. These findings have potential impact along two
lines, to design new immune therapies for EBV-associated
malignancies, and to understand resistance of most healthy
carriers of EBV to transformation in vivo.
If one considers many EBV-associated malignancies,
such as Hodgkin’s lymphoma and nasopharyngeal carci-
noma, only a group of EBV latency genes are known to be
expressed, i.e., EBNA1, LMP1, and LMP2 (14). Two of
these can be presented through the exogenous pathway by
DCs: EBNA1 on MHC class II (4) and in this paper, LMP2
on MHC class I. Furthermore, LCLs serve as targets for
these CD41 (4) and CD81 (this paper; Fig. 3) T cells.
Therefore, the cross-presenting ability of DCs, or the spe-
cific loading of DCs with CD41 T cell (EBNA1) and
CD81 T cell (LMP2) antigens, might be explored in DC-
mediated active immunization against EBV-associated ma-
lignancy. By charging DCs with necrotic rather than apop-
totic LCLs, there will be much less carryover of viable
tumor (Fig. 1 A). Importantly, by using DCs rather than
tumor cells as the antigen, one can exploit the distinct ca-
pacity of DCs (relative to B cells) to produce high levels of
IL-12 (15) and prime efficiently in the T cell areas (16).
Even a stable stock of allogeneic LCLs could be feasible for
charging DCs for immunotherapy, especially in cases in
which autologous LCLs or tumor are difficult to obtain.
Although the DCs will likely process allogeneic peptides
from the LCLs (the so-called indirect pathway of allo-
MHC presentation) in addition to viral latency antigens,
the former antigens may provide helper function during
immunization. In our hands, allogeneic MHC molecules
on dead LCLs were not directly stimulatory for T cells,
presumably because allo-MHC and/or necessary costimu-
latory molecules did not maintain their native conforma-
tions in sufficient number on dead LCLs (Fig. 2 A). While
this manuscript was under review, stimulation of LCL-spe-
cific CD81 T cells was achieved by another group using
DCs loaded with LCL lysates (17). Cross-presentation from
Figure 5. T cells, generated by DCs cross-presenting allogeneic LCLs,
have a high functional affinity. Titration of FLGRAYGL peptide in the
ELISPOT assay after expansion with DCs loaded with synthetic
FLGRAYGL peptide or dying necrotic LCLs. SFC, spot-forming cell.410 Cross-Presentation of EBV Latency Antigens by Dendritic Cells
allogeneic LCLs is most likely due to processing of EBV la-
tency–specific peptides from proteins or larger protein frag-
ments in the dead LCLs, as small peptide epitopes have
very short half-lives in cells lacking their restricting HLA
molecules (18) and are therefore found in only trace
amounts in allogeneic LCLs.
The two latency antigens we have investigated for cross-
presentation are of special interest for defense against EBV
in vivo. LMP2 is the only EBV transcript expressed by
EBV1 blood memory B cells from healthy donors (19).
LMP2 is thought to provide a growth signal comparable to
that delivered via src-family kinases and the B cell receptor
(20). LMP2 also is a major EBV latency antigen expressed
in Hodgkin’s lymphoma (14), against which CD81 T cell
reactivity can be detected, at least in some HLA-haplotypes
(21, 22). These features make LMP2 potentially important
for the induction of protective CD81 T cell immunity, in-
cluding for DC-mediated therapy against EBV-associated
malignancy. EBNA3A cross-presentation demonstrates the
efficiency of the exogenous pathway in DCs. The EBNA3
proteins are expressed at lower levels than other EBV latent
antigens (23), and only 1–30 MHC class I–complexed
EBNA3 peptides per cell can be detected on the LCL sur-
face (24). In our studies, we reproducibly observed cross-
presentation of LMP2 and EBNA3A when we loaded just
one dying LCL per DC.
We suspect that cross-presentation can begin in vivo dur-
ing the lytic acute phase of EBV infection (infectious
mononucleosis), when the number of dying infected B cells
must be massive. The immune response to EBNA1, which
is essential for the maintenance of the EBV episome during
host cell division, is providing the first evidence for cross-
presentation of EBV antigens to CD41 and CD81 T cells in
vivo. The Gly-Ala repeat region of EBNA1 inactivates the
proteasome in cis, blocking its presentation on MHC class I
by the endogenous pathway (25). However, EBNA1-spe-
cific CD81 T cells are known, and these require exogenous
loading of MHC class I molecules for presentation (26, 27).
We have found that DCs also process EBNA1 from trans-
formed LCLs onto MHC class II, expanding EBNA1-spe-
cific, CD41 T cells (4). This may occur in vivo, as the
CD41 T cell response in healthy carriers is primarily of the
Th1 type (28). As B cells are not known to be efficient in
producing IL-12 or polarizing T cells to Th1, whereas DCs
are efficient in both regards, IL-12–producing, cross-pre-
senting DCs may induce these EBNA1-specific Th1-type
CD41 T cells in vivo. Therefore, we suggest that the im-
mune response to EBV may depend substantially on the
cross-presentation of EBV-infected cells by DCs.
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